Clinical Trials Logo

Stimulant Use clinical trials

View clinical trials related to Stimulant Use.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05787847 Not yet recruiting - Stimulant Use Clinical Trials

Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program

Start date: February 2024
Phase: N/A
Study type: Interventional

The goal of this randomized control pilot study is to learn about a financial incentives intervention among individuals who use stimulants and take part in a community-based syringe exchange program. The main question it aims to answer is how financial incentives for not using stimulants will impact stimulant use. Participants in the experimental group will have the opportunity to earn financial incentives for providing a negative urine sample for stimulants using a point-of-care test, which indicates abstinence from stimulant use, along with health education on the health risks of stimulant use and substance injection. Researchers will compare the experimental group to the control group who will receive health education on the health risks of stimulants use and injection.

NCT ID: NCT05097547 Not yet recruiting - Clinical trials for Contingency Management

Contingency Management for Stimulant Use Disorders

Start date: October 2021
Phase: N/A
Study type: Interventional

The invetigators' objective is to implement Medication Assisted Treatment (MAT) and contingency management in patients affected by co-occurring opioid use disorder and stimulant use disorder. Participants will continue to receive standard of care for their opioid use disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants' stimulant use disorder will be targeted through contingency management, with twice weekly urine drug screens and monetary prizes in exchange for negative urine drug screens. Through regular clinic visits and the use of incentives, the investigators hope to increase treatment adherence and increase the number of negative urine drug screens in subjects struggling with co-morbid opioid use disorder and stimulant use disorder. The investigators will determine whether or not this treatment is effective in this population, versus conventional treatment (baseline therapy patients were getting through OBOT). The investigators' primary outcome measure will be stimulant abstinence duration during the twelve week study.